The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design by Rey, Felix et al.
HAL Id: hal-02346839
https://hal.archives-ouvertes.fr/hal-02346839
Submitted on 23 Dec 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
The bright and the dark side of human antibody
responses to flaviviruses: lessons for vaccine design
Felix Rey, Karin Stiasny, Marie-Christine Vaney, Mariano Dellarole, Franz
Heinz
To cite this version:
Felix Rey, Karin Stiasny, Marie-Christine Vaney, Mariano Dellarole, Franz Heinz. The bright and the
dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Reports,
EMBO Press, 2018, 19 (2), pp.206-224. ￿10.15252/embr.201745302￿. ￿hal-02346839￿
Review
The bright and the dark side of human antibody
responses to flaviviruses: lessons for vaccine design
Félix A Rey1,2,* , Karin Stiasny3, Marie-Christine Vaney1,2, Mariano Dellarole1,2 & Franz X Heinz3,**
Abstract
Zika and dengue viruses belong to the Flavivirus genus, a close
group of antigenically related viruses that cause significant arthro-
pod-transmitted diseases throughout the globe. Although infection
by a given flavivirus is thought to confer lifelong protection, some
of the patient’s antibodies cross-react with other flaviviruses with-
out cross-neutralizing. The original antigenic sin phenomenon may
amplify such antibodies upon subsequent heterologous flavivirus
infection, potentially aggravating disease by antibody-dependent
enhancement (ADE). The most striking example is provided by the
four different dengue viruses, where infection by one serotype
appears to predispose to more severe disease upon infection by a
second one. A similar effect was postulated for sequential infec-
tions with Zika and dengue viruses. In this review, we analyze the
molecular determinants of the dual antibody response to flavivirus
infection or vaccination in humans. We highlight the role of
conserved partially cryptic epitopes giving rise to cross-reacting
and poorly neutralizing, ADE-prone antibodies. We end by propos-
ing a strategy for developing an epitope-focused vaccine approach
to avoid eliciting undesirable antibodies while focusing the
immune system on producing protective antibodies only.
Keywords antibody neutralization; antibody-dependent enhancement; fla-
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Introduction
Flaviviruses are a worldwide threat to public health, as exemplified
by the global spread of dengue with an estimated 390 million annual
infections [1], the explosive Zika virus epidemics across the Pacific,
South and Central America since 2013 [2], and the inherent danger of
urban yellow fever in Africa and South America [3,4]. The major
driver of these epidemics is the virus transmission by peridomestic
Aedes aegypti mosquitoes, which constitute the amplification motor
in urban viral transmission cycles from human to human [5]. The
expansion of urban environments with insufficient infrastructure in
tropical and subtropical regions makes vector control extremely diffi-
cult and provides an ideal ground for the spread of Aedes-transmitted
viruses. In addition to the impact of urbanization, international travel
and trade facilitate the introduction of vectors and viruses into new
geographical environments, as exemplified by the dissemination of
the Asian tiger mosquito Aedes albopictus in the Americas and in
Europe [6]. Similarly, the omnipresence of Culex mosquitoes and
susceptible hosts has led to the expansion of West Nile virus through-
out the Americas at the turn of the century [7]. Other encephalitogenic
flaviviruses such as Japanese encephalitis (also primarily transmitted
by Culexmosquitoes) and tick-borne encephalitis viruses further illus-
trate the broad range of flavivirus diseases and natural cycles.
Although numerous compounds with anti-flaviviral activity have
been identified (reviewed in reference [8]), none has so far been
developed for clinical application. Efficient vaccines are available
for only a few flaviviruses—yellow fever, Japanese encephalitis,
and tick-borne encephalitis viruses [9–11]. Despite decades of inten-
sive efforts, an efficient vaccine against dengue virus is not avail-
able. The vaccine Dengvaxia, currently licensed in certain endemic
countries, provides suboptimal protection and is not recommended
for children under 9 years of age (reviewed in [12,13]).
We discuss here the structural aspects of the interaction of fla-
vivirus particles with antibodies, in particular those features that
relate to virus neutralization and antibody-mediated mechanisms
that may potentially aggravate disease. We do not discuss the anti-
body response against the non-structural protein NS1, which can
contribute to protection (by mechanisms that are unrelated to parti-
cle neutralization), but has also been implicated as a factor in
dengue pathogenesis [14]. Similarly, the patient’s T-cell response,
which is another important aspect of protection and pathogenesis, is
also outside the scope the present review.
We recently reviewed structural determinants that may contri-
bute to the broad tropism of flaviviruses [15], which mainly derive
from the heterogeneity of the viral particles as a result of their
complex morphogenetic pathway. This heterogeneity is particularly
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important in the case of the dengue viruses. We also analyzed the
impact of the dynamic behavior of the envelope protein and its
potential for exposing alternative surfaces for the interaction with
receptors for entry. Here we discuss those same properties of the fla-
vivirus particle in relation to its interactions with the humoral
immune system. We analyze the reasons for the double-edged
sword properties of antibodies against dengue virus—having a
protecting role but also a disease enhancing potential—and
conclude by providing elements for the design of engineered
immunogens that avoid the drawbacks of the dengue virus humoral
immune response in humans, while focusing on the induction of
protective antibodies only. Such a subunit vaccine approach has the
potential of protecting both against dengue and Zika viruses.
Early landmarks in flavivirus research
The name flavivirus derives from latin (flavus = yellow) in relation
to yellow fever virus, the type-species of the genus [16] and, in
1900, the first identified virus infecting humans [17]. Yellow fever
was also the first disease for which transmission by infected
mosquitoes had been already proposed and demonstrated at the end
of the 19th century [17,18]. A major breakthrough was the develop-
ment in the late 1930s of an attenuated strain of the virus, called
17D [19], which is still today one of the most efficient vaccines
against any virus [20]. The determination of the nucleotide
sequence of the yellow fever virus genome in 1985 [21] opened the
flavivirus molecular biology era. Flaviviruses were then assigned as
a genus within a new family [22], separate from the arboviruses in
the family Togaviridae. The new classification matched the “group
B” arboviruses, which were serologically defined back in the 1950s
by Casals and Brown [23] using hemagglutination inhibition assays.
In these assays, all the flaviviruses tested exhibited considerable
cross-reactivity, demonstrating that they displayed common anti-
gens. This broad cross-reactivity contrasted with the neutralization
patterns, which were much more specific for the flavivirus against
which the antibodies were raised [24].
Flavivirus structural biology
The structure of flavivirus particles
Flaviviruses are small icosahedral enveloped viruses, composed of a
positive-stranded RNA genome (Fig 1A) and only three structural
proteins: C (capsid), E (envelope), and prM (precursor of membrane)
in immature virions or M (membrane) in mature virions (Fig 1B–E).
The E protein mediates cellular attachment and membrane fusion
after virus uptake by receptor-mediated endocytosis. The membrane
fusion process is triggered by the acidic pH in the endosomes and is
driven by extensive conformational and oligomeric rearrangements
of E that lead to the formation of a post-fusion E trimer (Fig 2). Early
landmarks in the structural biology of flaviviruses have been the
high-resolution structure of the envelope protein E of tick-borne
encephalitis virus [25] and of dengue virus type 2 in the pre-fusion
dimer form [26] and in their post-fusion trimer conformations
[27,28] (Figs 1 and 2); a first cryo-EM structure resolving the organi-
zation of the E dimers at the surface of mature dengue virus serotype
2 particles [29], the X-ray structure of the prM/E heterodimer of
dengue virus [30], and the cryo-EM structure of the dengue virus
serotype 2 immature particle [31]. These were followed by the cryo-
EM structures of the mature particles of dengue virus serotypes 2
[32] and 4 [33] to a resolution of 3.5 A˚ and 4 A˚, respectively. A
number of important structures obtained by cryo-EM were reported
recently, such as the structures of Zika virus [34,35] and Japanese
encephalitis virus [36] particles also at around 4 A˚ resolution. In
addition, numerous X-ray structures of complexes of the E protein
(or individual domains) with antibody fragments were reported, as
well as cryo-EM structures of the particles in complex with antibod-
ies, which have been the focus of extensive recent reviews [37–40].
Flavivirus particles and pH sensitivity
The mature particle The mature particles of flaviviruses all display
the same architecture (Fig 1D and E), exposing 180 E proteins orga-
nized as dimers in a herringbone pattern. Contrary to what is often
quoted, this icosahedral architecture does not conform to a T = 3
surface lattice (which would also yield 180 = T*60 subunits), as the
E proteins do not follow the quasi-equivalence principle [41], mean-
ing that the three E proteins in the icosahedral asymmetric unit
display non-equivalent interactions. This feature is also relevant for
antibody recognition, as a given epitope on protein E will be
displayed in three different environments on the mature particle.
The fusogenic conformational change The mature E dimer at the
particle surface corresponds to a metastable form of the protein that
is sensitive to the mildly acidic environment of the endosomes,
reflecting the receptor-mediated endocytic pathway of flavivirus
entry [42]. Conformational changes of E have been shown to be trig-
gered already at the pH of early endosomes (6.5–6.0 [43]) but at
least in the case of dengue virus, fusion may also depend on acidic
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lipids found in late endosomes [44]. The pH sensitivity of flavivirus
particles leads to their inactivation when exposed to an acidic envi-
ronment in the absence of target cells [45,46]. Particle inactivation
is caused by an exothermic, irreversible conformational change of
E [27,28] triggered upon binding of protons. When this change
takes place in an endosome, it catalyzes the fusion reaction
between viral and endosomal membranes. This step is essential for
releasing the viral genome into the cytoplasm. The fusion mecha-
nism (Fig 2A and B) includes dissociation of the E dimer, which
then exposes the fusion loop at the tip of domain II to insert into
the inner endosomal membrane leaflet. The two membranes are
thereby bridged by the E proteins, which trimerize during this tran-
sient extended intermediate conformation. The subsequent re-loca-
tion of domain III to the side of the trimer projects the stem and the
transmembrane region toward the tip of domain II, forcing the
close apposition of viral and endosomal membranes at the same
end of the post-fusion trimer, thereby catalyzing membrane fusion
(reviewed in reference [47]). The final, stable trimer thus has the
three E subunits in the characteristic hairpin conformation (Fig 2A
and B, right panels) observed in the post-fusion forms of all three
characterized structural classes of viral fusion proteins [48]. The E
protein is therefore a “suicidal” catalyst that acts only once, after
which it becomes non-functional and is degraded in the lysosomes.
The acid sensitivity of the flavivirus particle also requires a built-
in mechanism to keep the inactivating conformational change of E
from taking place prematurely, because the newly synthesized parti-
cles are exposed to acidic pH during their transit through the trans-
Golgi network (TGN) in the course of exocytosis [42]. Flavivirus
virions therefore assemble in the endoplasmic reticulum (ER) in an
immature, non-infectious form (Fig 1B and C), which is activated
for membrane fusion only after proteolytic maturation in the acidic
environment of the TGN [30], as described below.
◀ Figure 1. Flavivirus particle assembly.(A) The flavivirus open-reading frame coding for a single precursor polyprotein. Co- and post-translational proteolytic processing results in the various proteins indicated, with
structural and non-structural proteins in red and blue, respectively. (B–E) Sketches representing the flavivirus particle at different maturation stages (left), with a ribbon
representation of the relevant envelope protein complexes on the right. The genomic ribonucleoprotein complex with protein C has not been visualized and is
represented here within a central gray circle (in B–D), although its organization is unknown. Protein E is colored according to domains: red, yellow, blue, and green for domains
I, II, III, and stem/TM (transmembrane anchor), respectively. The fusion loop is highlighted in orange, and prM/M (including its TM region) is shown in pink. The viral
membrane is represented in gray. (B) Left: The immature flavivirus particle as it buds in the ER of the infected cells. Right: A single (prM/E)3 spike is displayed as ribbons (PDB
code 4B03). (C) Left: The immature flavivirus particle after exposure to the acidic pH of the trans-Golgi apparatus, where the trimeric spikes dissociate and the 180 prM/E
heterodimers re-associate into 90 (prM/E)2 dimers. Right: A single (prM/E)2 dimer is shown as ribbons (PDB codes 3C6R and 3JP2). (D) Left: Themature flavivirus particle with 90
(M/E)2 dimers. Right: A single (M/E) 2 dimer is shown in ribbons. (E) Left: Herringbone pattern of E dimers on the surface of mature virus particles, consisting of 30
rafts of three E dimers. One raft is framed in black. Right: Top view of a single E homodimer shown as ribbons.
Endosomal membrane
Viral membrane
B
A
Figure 2. The fusogenic conformational change of the E protein during cell entry.
The E protein is colored as in Fig 1. (A) Schematic of the fusion process: A mature E dimer anchored in the viral membrane is represented in the left panel. The dimer dissociates
upon exposure to acidic pH in the endosome, inserting the fusion loop into the endosomal membrane (second panel). The aligned E monomers then trimerize, thereby
creating a binding site for domain III at the sides of a “core trimer”. Domain III then flips to the sides of the trimer, pulling the stem and TM segments toward the
endosomal membrane (third panel). The final, post-fusion conformation, brings the viral TM segment next to the fusion loop, inducing first hemi-fusion (i.e., fusion of only the
outer leaflets of the two membranes) followed by opening of a fusion pore (fourth panel). The final post-fusion conformation of E is achieved only after fusion pore
formation. (B) 3D structures of the dengue virus 2 E ectodomains (lacking the stem/TM regions) matching the steps indicated in (A) (PDB codes 1OAN and 1OK8 for pre-fusion
and post-fusion conformations, respectively).
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Flavivirus particle assembly In the infected cell, genome replication
takes place within membrane invaginations at the cytosolic side of
the ER [49]. The newly synthesized genomic RNA associates with
the core protein C (Fig 1) to form a ribonucleoprotein (RNP)
complex. The role of protein C in this process and the organization
of the resulting RNP are still not understood [50]. Budding of the
RNP across the ER membrane appears to be driven by the viral
transmembrane glycoproteins prM and E, which can lead to budding
of empty particles in the absence of the RNP (reviewed in [42]). The
two glycoproteins form heterodimers that in turn associate into
(prM/E)3 trimeric spikes projecting into the ER lumen [42]. The
spikes interact laterally to induce curvature, resulting in formation
of a closed icosahedrally symmetrical particle displaying 60 spikes
(Fig 1B). These particles, which accumulate in the neutral pH ER
lumen to then be transported across the exocytic pathway, are also
pH sensitive. As shown for dengue virus, they react to the TGN’s
acidic environment by undergoing a reversible conformational
change. The 60 (prM/E)3 trimers thus convert into 90 (prM/E)2
dimers (Fig 1C), generating the characteristic herringbone-like
arrangement of E, which remains in mature virions [30] (Fig 1E).
Through this conformational change, prM exposes a specific cleav-
age site for furin, a TGN-resident protease [51], which cleaves prM
in the linker between its N-terminal globular head (containing
roughly 80 amino acids, termed pr) and the C-terminal, transmem-
brane stub (also about 80 amino acids, termed protein M). This
proteolytic step renders the conformational change of the particle
irreversible. The pr globular domain remains bound as long as the
pH is acidic, keeping E from undergoing the fusogenic conforma-
tional change. Its affinity for the E dimers drops substantially at
neutral pH and is therefore shed from the virion upon release into
the extracellular, neutral pH environment [30], giving rise to acti-
vated mature particles that are ready to infect other cells (Fig 1D
and E).
Particle heterogeneity and dynamics
Two important main features derive from the complex flavivirus
morphogenesis pathway and the metastability of the exposed E
dimer, both of which are a requirement for the particle to react to
the environmental pH:
1 Furin processing is often incomplete, resulting in mosaic parti-
cles (reviewed in reference [52]) as documented for dengue
virus [53,54]. The fusion loop and other conserved regions of
the E protein are exposed in the immature areas of these parti-
cles (Fig 3A and B), with important consequences for the
specificity of antibodies induced and their interaction with
virus particles.
2 The reactivity to acid pH also implies that the E dimers in the
“activated” form are metastable and display a dynamic behav-
ior (reviewed in reference [55]) commonly referred to as virus
“breathing”. The kinetics of breathing are strain specific,
and—like particle heterogeneity—affect the interaction with
antibodies. Antibody binding to transiently exposed epitopes
can also induce exposure of the fusion loop to insert into the
plasma membrane for cell entry in the absence of a receptor,
in a novel ADE mechanism described recently [56], or modu-
late antibody responses [57]. This breathing also allows
sporadic binding of circulating antibodies targeting the fusion
loop in sub-neutralizing stoichiometry, leading to entry via Fcc
receptors present in some cells in a classical ADE context.
Both of these properties, particle heterogeneity and dynamic
“breathing” behavior, therefore contribute to the biological and anti-
genic characteristics of flaviviruses. Certain strains of dengue virus
serotype 2 were shown to adopt a different, expanded conformation
of their mature particles, termed “bumpy” [58,59] upon incubation
at temperatures above 34°C. This change was irreversible, unlike
the “breathing” behavior discussed above, suggesting that in those
particles the envelope protein was trapped in a local energy mini-
mum such that the particles could be visualized by single particle
cryo-EM with icosahedral averaging. In other strains, this “bumpy”
arrangement has not been observed, which may be due simply to
the fact that such local minimum energy state is not always avail-
able, and the E dimers reversibly move about the local minimum in
the herringbone conformation. The highly dynamic behavior also
leads to a rapid particle inactivation, which is accelerated with
temperature (reviewed in [55]).
The possible reasons for flaviviruses to maintain these properties
most probably have to do with interactions for entry, as the diver-
sity of circulating forms may allow them to expand their host and
tissue tropism, as discussed recently [15]. The antigenic complexity
conferred by particle heterogeneity and dynamics may also
confer them an advantage in the vertebrate hosts by exploiting non-
protective antibody responses to favor subsequent heterologous
infections.
The antigenic landscape of flaviviruses
Most of the residues exposed at the external surface of the E dimers
in the mature herringbone lattice are not conserved and are specific
to each virus (Fig 4A and B). Antibodies directed against this
surface therefore potently neutralize the autologous and closely
related viruses only. This criterion of cross-neutralization by
polyclonal sera has led to the classification of flaviviruses into
serocomplexes [24].
Over the years, large panels of mostly murine monoclonal anti-
bodies (Mabs) were obtained through immunization in a variety of
ways, using recombinant fragments of protein E, or using inacti-
vated virus and also live virus. Later, human Mabs were isolated
from vaccinated or naturally infected individuals. The resulting
Mabs revealed a broad range of neutralizing potencies, with the
most potent Mabs neutralizing in the ng/ml range (reviewed in
references [37,39]), indicating that polyclonal sera contain a mixture
of antibodies with different degrees of neutralizing activities and
cross-reactivities.
A number of the epitopes of neutralizing Mabs were character-
ized structurally by X-ray crystallography of Fab or scFv fragments
in complex with the soluble E (sE) protein (i.e., lacking the stem
and trans-membrane regions), and by cryo-EM of complexes with
mature particles. The epitopes identified were generally conforma-
tional and comprised discontinuous segments of the E polypeptide
chain. Some localized to single domains, such as those encompass-
ing the lateral ridge of domain III—exemplified by the murine anti-
body E16 against West Nile virus [60]. Epitopes have also been
identified on domain I, like the epitope of the chimpanzee Mab 5H2
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specific for dengue virus serotype 4 [61]. Other antibodies target the
hinge region between domains I and II, such as Mab 1F4 which
potently neutralizes dengue virus serotype 1 [62]. Other Mabs bind
more complex assemblies and were found to be dependent on the
quaternary structure of E, such as Mab 2D22, which is specific for
dengue virus serotype 2 [63] and the “EDE” antibodies described
below. Finally, several antibodies were found to bind across E
dimers arranged in the herringbone pattern, such as the West Nile
virus-specific Mab CR4354 [64], the dengue virus serotype 1-specific
Mab 14c10 [65], the dengue virus serotype 3-specific Mab 5J7 [66],
and the Zika virus-specific antibody ZIKV-117 [67].
Overall, the surface of flavivirus particles appears to display a
continuum of epitopes with different degrees of structural complex-
ity that can induce potently neutralizing antibodies.
EDE antibodies
Although the exposed E protein surface on mature virions is essen-
tially variable and most strongly neutralizing Mabs are virus type-
specific, the E dimers also expose a vulnerable region, termed
“EDE” for “E dimer epitope”, which is targeted by antibodies with a
broader spectrum of viruses they potently neutralize [68]. For
instance, EDE antibodies can cross-neutralize all four serotypes of
dengue virus, and some can also potently neutralize Zika virus [69],
which does not formally belong to the dengue serocomplex. The
EDE is more conserved than other regions at the surface of E
(Fig 4A), because it is the binding site of prM during the particle
maturation process in the Golgi apparatus of the infected cell
(Fig 1). This conserved patch exposes the main chain of b-strand b
at the tip of domain II and is therefore relatively insensitive to side
chain alterations on this strand. It also includes the exposed part of
the fusion loop, corresponding mainly to the main chain of glycine
residues in this area, as the strictly conserved non-polar side chains
are buried in the dimer contact with domain III from the adjacent E
subunit. The fusion loop surface is partially protected by an aspara-
gine-linked glycan on the variable “150 loop” of the opposite E
subunit in the dimer. Antibodies targeting this epitope are divided
into two subclasses, EDE1 and EDE2, depending on the recognition
of the conserved glycan at Asn153 of dengue virus. EDE1 antibodies
do not require glycosylation for binding, whereas EDE2 antibodies
strongly rely on the glycan for binding. The crystal structures of
these antibodies in complex with the E protein showed that the
EDE1 Mabs induce disorder of the 150 loop and the glycan, and
recognize also the domain III surface that interacts with the fusion
loop on the adjacent subunit, partially overlapping the epitope of
the dengue virus serotype 2-specific 2D22 antibody discussed above.
The EDE2 antibodies, in contrast, do not interact with domain III.
FL FL
FL
SIDE VIEW TOP VIEW
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Figure 3. The fusion loop is exposed in the immature (prM/E)3 spikes.
Left panels: side views, right panels: top views. (A) The spike shown in ribbons as in Fig 1. (B) The spike shown in a surface representation colored according to amino acid
conservation across all flaviviruses, from white (variable) to dark blue (absolutely conserved). Patches corresponding to the fusion loop are indicated by orange arrows.
One of the three fusion loops in the trimer is not exposed (orange dashed arrow).
ª 2017 Institut Pasteur EMBO reports Vol 19 | No 2 | 2018
Félix A Rey et al Flaviviruses and interactions with antibodies EMBO reports
211
The EDE1 antibodies were shown to also potently neutralize Zika
virus, whereas the EDE2 Mabs displayed only intermediate neutral-
izing potency, mainly because the glycan on the 150 loop in the Zika
virus E protein (which is linked to Asn154) is shifted by about 10 A˚,
as shown in the crystal structure [69], and the binding affinity is
therefore substantially reduced.
EDE antibodies bind partially mature particles equally well as fully
mature virions In spite of being incompetent for binding to fully
immature dengue virus particles (which do not expose an E dimer
at their surface, see Fig 5A), the EDE MAbs were found to bind viri-
ons having over 60% uncleaved prM as efficiently as they bind fully
mature particles, which expose only dimers at their surface [68].
This result can be explained by the fact that in fully immature parti-
cles, the 60 (prM/E)3 trimeric spikes form a tightly intertwined
lattice, in which each trimer is supported by three adjacent trimers
[70], such that there are as many intra- as inter-spike stabilizing
interactions (Fig 5A). When one-third of the prM molecules are
cleaved, there are two possibilities: either random cleavage, in which
on average each trimeric spike will be destabilized by the absence of
one of the three prMs, or non-random cleavage leaving regions of
uncleaved prM on one side of the particle, forming a “spiky patch”,
with the rest of the virion displaying the smooth, mature herringbone
arrangement. Structural studies on dengue virions have shown this
second possibility to actually be the case [53,54], which is likely a
reflection of the membrane-anchored nature of furin, such that under
limiting furin expression, only the side of the virion closest to the
TGN membrane will be processed. The (prM/E)3 trimers at the inter-
face between immature and mature patches will lack the stabilizing
effect of three adjacent trimers and will more easily flip reversibly to
180°
TOP VIEW BOTTOM VIEWA
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100%
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50 nm
Figure 4. The mature particle exposes a conserved patch.
(A) The E dimer in surface representation colored according to amino acid conservation across all flaviviruses, in its top and bottom view. The pr binding site is encircled
in pink. This site corresponds to the conserved E dimer epitope (EDE) discussed in the text. Notice the high conservation of the E dimer “underside” in the “bottom” view (right
panel), which faces the viral membrane in the particle. (B) The mature flavivirus particle shown in surface representation, colored as in (A). One dimer is highlighted by a
red contour. The black box indicates the region zoomed in the right panel.
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(prM/E)2 dimers, generating a substrate for EDE Mab binding.
Because the affinity of the EDE antibodies for the E dimer is very
high, they shift the equilibrium toward the dimeric form while
displacing the uncleaved prM (Fig 5B).
Antibodies targeting cryptic epitopes
Several epitopes have been described that would be inaccessible for
antibody binding in a compact assembly of E proteins in mature
virions (Fig 1E) and were therefore designated cryptic epitopes. The
most prominent of these include epitopes at different sites of
domain III and the fusion loop epitopes (FLEs).
Domain III epitopes Examples of partially cryptic epitopes are those
of the murine dengue virus-specific Mabs 1A1D2 [71] and 4E11
[72], which target the A strand in domain III and can neutralize
several serotypes, and also the 2H12 antibody targeting the AB loop
45°
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Figure 5. Differential binding modes of EDE versus FLE antibodies (Abs).
(A) Left panel: Intertwined lattice of (prM/E)3 trimers in the spiky immature particles. A central (prM/E)3 spike is represented with protein E colored by domains as in Fig 1.
All other spikes have protein E in gray. prM is displayed in pink throughout. A box highlights the region zoomed in themiddle panel. Middle panel: intertwined array of (prM/E)3
spikes, in which the three adjacent trimers (A, B, and C) interact underneath the central one (black arrows), underpinning it. In partially immature spikes, such stabilization is
lost for the trimers at the interface between spiky and mature patches. Right panel: View along the white arrow of the middle panel, rotated by 45°. The black arrows
point to the contacts between adjacent spikes. (B) Interaction of partially mature particles with EDE (green) and FLE (blue) antibodies. The spikes at the interface between
mature and immature patches do not have the underpinning and stabilizing effect of three surrounding spikes shown in (A), and are therefore destabilized at these edge
regions. The very high affinity of the EDE antibodies for the E dimer appears to shift the trimer-dimer equilibrium toward dimers at the interface. Inner trimers become
destabilized in turn upon EDE antibody binding, resulting in a domino effect such that the particle ends up fully coated with antibodies, as illustrated in the middle, top panel.
FLE antibodies, in contrast, can readily bind to the immature patches, but also to the mature side depending on the extent of breathing (see panel C). (C) Interaction of mature
particles with EDE (green) and FLE (blue) antibodies. Particle breathing (indicated by curved black arrows) leads to transient exposure of the fusion loop. EDE antibodies
bind readily, regardless of the breathing behavior of the E dimers. FLE antibodies can only bind when the fusion loop is exposed through breathing, allowing particle
internalization via Fcc receptor-mediated endocytosis before attaining sufficient antibody coating for neutralization depending on the breathing kinetics, giving rise to ADE.
This situation can also explain why neutralizing antibodies, if present with ADE-prone antibodies such as the FLEs, can override ADE by completing the antibody coating,
without the need to displace the bound FLE antibody.
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of domain III [73]. A special case is the dengue virus type 1-specific
antibody E111 [74], which targets an entirely buried surface of
domain III between E dimers in the herringbone pattern (the CC’
loop in domain III). This is the only antibody described so far that is
specific for a cryptic epitope and strongly neutralizing, but this
activity is restricted to a laboratory-adapted strain exhibiting a
highly dynamic behavior of the E protein [75]. For Zika virus, two
similar mouse antibodies, ZV-48 and ZV-64, both targeting the CC’
loop, were shown to neutralize only one out of several strains,
suggesting a different breathing mode for susceptible strains, which
affects the packing of dimers at the particle surface [76].
Fusion loop epitopes Fusion loop epitopes are defined as an ensem-
ble of epitopes comprising the fusion loop, which is normally buried
in the E dimer. Binding to the FLEs therefore requires dimer dissoci-
ation. Because the amino acid sequence of the fusion loop is
conserved across flaviviruses, antibodies targeting the FLE are
broadly flavivirus cross-reactive. The majority of them specifically
recognize the side chain of the strictly conserved Trp101 of the
fusion loop, as shown by structural studies [53,77]. FLE antibodies
are reactive in immunoblots only under non-reducing conditions, as
several disulfide bonds stabilize the conformation of the fusion loop.
The FLEs are exposed in the immature patches (Figs 3 and 5B) of
the mosaic particles resulting from incomplete furin maturation
[53,54], in line with the observation that partially mature virus
preparations are more sensitive to neutralization by patients serum
than fully mature particles (reviewed in reference [78]). Consistent
with the cryptic nature of FLEs in mature virions, Pierson and
colleagues have demonstrated, using West Nile virus, that antibod-
ies targeting the FLEs can bind such particles only upon “breathing”
of the E dimer (illustrated in Fig 5C). The breathing rate is strain
dependent, as discussed below, and affects the neutralization poten-
tial of these antibodies [79].
The extent of breathing and the exposure of the fusion loop are
apparently controlled by sequences outside the FLEs. When Serafin
and Aaskov obtained escape mutants of the FLE antibody 4G2, the
corresponding mutations did not map to the fusion loop, but to resi-
dues elsewhere in the E protein [80], which presumably control FLE
exposure by affecting the breathing rate. Similarly, the kinetics of
breathing were shown to be strain dependent (reviewed in reference
[81]) and single mutations of the E protein were found to have a
strong impact on the overall reactivity of the particle with antibodies
targeting cryptic epitopes [75,82]. Although there have not been
systematic experiments addressing breathing rates for many strains,
it is currently being recognized that laboratory-adapted dengue virus
strains are much more dynamic than clinical strains, exposing cryp-
tic epitopes more easily and behaving differently in neutralization
tests [83]. The highly dynamic behavior of such strains can also lead
to greater instability of virus preparations and more rapid loss of
infectivity [79]. Such particle instability may not be a disadvantage
under the conditions used in cell culture, but is likely to be selected
against in naturally circulating viruses, in particular for flaviviruses,
which go back and forth between arthropod and vertebrate hosts.
The amino acid sequence conservation of the fusion loop,
together with its exposure at acid pH to drive membrane fusion
provides a framework to understand the early findings that led to
the serological classification of the flaviviruses (then classified as
“Group B Arboviruses”) by hemagglutination inhibition (HI) assays
[23]. For certain viruses, for instance influenza virus, hemagglutina-
tion relies on binding of the viral hemagglutinin to sialic acid (the
influenza virus receptor) present at the surface of red blood cells
[84]. In the case of flaviviruses (as well as other arboviruses),
hemagglutination requires acid treatment [85], leading to E dimer
dissociation and exposure of the fusion loop, which then inserts into
the plasma membrane of red blood cells, inducing their agglutina-
tion around virus particles. This means that a substantial proportion
of antibodies in the sera that are positive in HI tests can be assumed
to bind FLEs and thus interfere with membrane insertion, explaining
their broad cross-reactivity.
Immune responses to FLEs Differences in the dynamics and hetero-
geneity of flavivirus particles may not only affect the mechanisms of
virus neutralization (see below) but may also skew the antibody
response toward certain epitopes. This effect appears to be espe-
cially prominent in dengue virus infections, in which a majority of
antibodies were found to be cross-reactive and poorly neutralizing,
targeting the immunodominant FLEs [86–91]. Importantly, the anti-
body response to prM was also found to be particularly strong in
dengue virus infections [87–89]. These antibodies have no or only
marginal neutralizing activity, and their epitopes have been mapped
to a single dominant site in dengue prM [92] or to complex quater-
nary epitopes encompassing surfaces from both prM and E [88,92].
Although the degree of maturity of viruses circulating in dengue
virus-infected patients has not been determined, the strong induc-
tion of prM-specific antibodies may be an indirect indicator for the
circulation of partially mature virions. Since the FLEs are accessible
in the immature patches of such particles (Fig 3), their presence
may contribute significantly to the dominance of FLE antibodies in
dengue virus infections [86–91].
In secondary infections with dengue or other flaviviruses, the
dominance of FLE antibodies is likely to be a consequence of the
original antigenic sin phenomenon that leads to preferential boosting
of pre-existing cross-reactive antibodies upon sequential infections
or immunizations with antigenically related molecules [93]. For
instance, a recent longitudinal study following the B-cell response of
Zika virus-infected individuals with a pre-existing memory of dengue
virus infection showed clear evidence of original antigenic sin in the
first few months of the infection, resulting only in cross-reactive anti-
bodies against dengue and Zika virus, which neutralized Zika virus
poorly. But in subsequent months, the same individuals had B cells
making potently neutralizing antibodies against Zika virus, which
were unrelated to the original ones and were not cross-reactive, co-
existing with the initial ADE-prone antibodies [94].
The presence in the patient’s serum of poorly neutralizing cross-
reactive antibodies together with strongly neutralizing serotype-
specific antibodies is responsible for the dual activity of the humoral
response against flaviviruses: It is important for protection, but in
certain instances may also aggravate disease via antibody-
dependent enhancement of the infection, as discussed below.
Interactions with antibodies
Antibody neutralization mechanisms
In order to develop efficient vaccines against closely related fla-
viviruses such as those in the dengue virus serocomplex, it is
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important to understand the mechanism of action of the strongly
neutralizing antibodies at the molecular level. Such an understand-
ing can provide clues to the correlates with protection. The main
target of neutralizing antibodies is the E glycoprotein, present in 180
copies at the particle surface, as described above (Fig 1D). The
mechanism of flavivirus neutralization by antibodies was initially
studied using West Nile virus, where neutralization was found to
follow a “multiple hit” model with a minimum antibody/virus parti-
cle stoichiometry [95], in line with the model for virion “coating” by
the antibodies proposed earlier for other viruses [96]. The minimum
stoichiometry for neutralization was shown to depend on the anti-
body, and for potently neutralizing antibodies, it was found that
occupancy of about 30 antibodies per particle was sufficient [95]. Of
note, for Mab E16, used in these experiments, the maximum
number of occupied epitopes by Fab fragments was found to be 120
and not 180 [60,97]. The reduced number of accessible epitopes is
due to partial occlusion of one of the three epitopes in the icosahe-
dral asymmetric unit, which in this case is also a consequence of
the lack of quasi-equivalence in the lateral interactions between E
dimers in the herringbone lattice (Fig 1E).
Neutralization by a “coat” of antibodies around the virus particle
can block its infectivity in multiple ways. One of them is by cross-
linking circulating virus particles via the two Fab arms of the anti-
body, reducing the number of available particles capable to infect
cells as the big cross-linked virus/antibody aggregates appear to be
efficiently cleared from the circulation [98]. For non-cross-linked
particles, there are essentially two options for neutralization: inter-
ference with receptor binding, and/or blocking the fusogenic confor-
mational change of the E protein once in the endosome, thereby
preventing membrane fusion.
Inhibition of the interactions with receptors In spite of decades of
intense investigation, there are still many unknowns remaining in
our understanding of flavivirus biology, in particular concerning the
entry pathways into relevant cells. A large body of studies on fla-
vivirus receptors have identified protein–protein interactions such
as domain III binding to integrins in the encephalotropic mosquito-
borne flaviruses, protein–sugar interactions like the DC-SIGN lectin
with the high-mannose glycans on the dengue virus E protein, and
interactions of phosphatidylserine lipids in the viral membrane with
TIM and TAM/Axl lipid receptors in the case of dengue, Zika, West
Nile, and yellow fever viruses (reviewed recently in [49,99]). Never-
theless, no single receptor has been identified that accounts for the
complete tissue tropism for any flavivirus as of today. As we
discussed in a previous review, the flavivirus maturation status
depends on the cell in which the particles were assembled, and the
resulting heterogeneity in turn allows the particles to employ dif-
ferent entry pathways to infect other cells, potentially using different
receptors and attachment factors depending on the particular tissue
[15].
An early study with murine antibodies against dengue virus iden-
tified that Mabs targeting E domain III were most efficient at block-
ing adsorption to cultured Vero cells [100], in line with the
proposed role of domain III for receptor binding—at least for some
flaviviruses and for infection of certain cells [101,102]. A similar
finding was obtained for the domain III-specific Mab 2B8 against
dengue virus serotype 2, which interferes with virus attachment to
BHK cells [103].
It follows from the apparent heterogeneity of flavivirus attach-
ment factors and entry receptors that determining the neutralization
potency of an entry-blocking antibody in tissue culture, that is, for a
given type of cell, may not necessarily reflect the situation in vivo.
For instance, if an antibody neutralizes by blocking the interaction
with DC-SIGN for entry into certain cells, the same antibody may
not neutralize the virus with respect to other receptors, for example,
integrins or the lipid receptors. This phenomenon may partially
explain the apparent lack of correlation between protection and
neutralization in cell culture observed with the antibodies elicited in
patients during the phase II and III dengue vaccine trials with
Dengvaxia [104–107] (see below).
Inhibition of membrane fusion Studies with polyclonal sera [108]
and Mabs (reviewed in reference [37]) have indicated that they may
confer neutralization at a post-attachment stage, most likely by
interfering with the conformational change required for membrane
fusion. Domain III, for instance, undergoes a drastic re-location
during this process, resulting in a hairpin-like structure of the E
protein that defines its post-fusion conformation (Fig 2). Targeting
this domain can therefore also block the conformational change and
impair membrane fusion, as elegantly shown for the potently
neutralizing Mab E16 directed against West Nile virus [60,109].
Moreover, a cryo-EM reconstruction of the West Nile virus coated
with the Fab fragment of E16 showed that upon acid treatment, the
bound Fab locks the particle in an intermediate expanded state, with
the E dimers at a higher radial distance from the viral membrane,
but unable to proceed to the fusogenic conformational change
[110]. Similarly, the chimpanzee Mab 5H2 targeting domain I and
the linker between domains I and III, which must extend to allow
re-location of domain III, was shown to block fusion of the virus
particles with fluorescently labeled liposomes [61].
Some of the most potently neutralizing Mabs are directed against
domain III [111,112]. While such antibodies constitute a substantial
proportion of the murine antibody response [113,114], they make
up only a minor fraction in human antibody responses against
dengue virus [88,89]. Their frequency, however, may increase in
individuals undergoing sequential flavivirus infections [94,111]. As
described above, many potently neutralizing antibodies were found
to recognize quaternary epitopes exposed at the surface of mature
virions (reviewed recently in [81,115,116]). These antibodies often
cross-link the E dimers at the particle surface and would interfere
with the conformational change to drive fusion [66,67,117]. An
important prerequisite for their neutralizing activity is that their
binding affinity remains high in the acidic environment of the endo-
some, as shown for Mab C10 and its interaction with Zika virus
[117]. The mechanism of neutralization by fusion inhibition can be
considered universal and not subject to variations in cell receptor
usage for infection of different tissues. The contribution of fusion
inhibition to overall neutralization, however, may be overestimated
in certain instances, because of possible pitfalls in the post-attach-
ment assays usually used for such analyses [66].
It is worth noting that antibodies capable of blocking fusion may
also interfere with receptor binding, such that the particle never
reaches the endosome. Such a dual activity is best illustrated by the
domain III-specific Mab E16, which inhibits both virus attachment
and fusion, as discussed above. In several instances, the neutral-
ization titers of Mabs were higher in pre-attachment than in
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post-attachment assay formats [67,100,103], suggesting that both
mechanisms may contribute to the overall neutralization. These
antibodies can therefore provide a double level of protection, such
that any particle that managed to interact with a receptor in spite of
being bound by the antibody, may still be blocked at the second step
of entry, within the endosome.
Antibody-dependent enhancement
A number of studies have shown that antibodies can not only
inhibit but also enhance flavivirus infection by providing an entry
pathway involving Fcc receptors. This phenomenon was clearly
shown in vitro for several flaviviruses using cultured cells bearing
Fcc receptors that are refractory to infection unless antibodies are
present (reviewed in [115,118,119]. The available evidence further
indicates that any antibody that can bind flavivirus particles without
neutralizing will cause ADE, even potently neutralizing antibodies
when present at sub-neutralizing concentrations [95]. But antibod-
ies targeting prM and the fusion loop of E appear to play an espe-
cially important role in ADE [87,88,92,120]. Both types of
antibodies were shown to be dominant components of the humoral
response of patients following a dengue virus infection [87,88], to
have low or no neutralizing potency, and to be strongly infection
enhancing in vitro [120] and in vivo [121].
Epidemiological observations provide indirect evidence for a
possible role of ADE on the course of natural dengue infections in
humans. Infants born to dengue-immune mothers were shown to
have a higher risk of developing severe forms of dengue disease
when infected in a time window in which the maternal antibodies
have dropped below the neutralization threshold [122]. To what
extent ADE caused by sub-neutralizing concentrations of maternal
antibodies is responsible for disease progression in these cases is
still controversial [123,124]. The first experimental in vivo model of
enhanced dengue disease severity through maternally acquired
heterotypic dengue antibodies was developed only recently [125]
and confirmed that this mechanism results in more severe disease
in mice.
In addition to potentially detrimental effects of maternally trans-
mitted antibodies, epidemiological studies have also shown that
the vast majority of severe dengue disease in children and adults
occurs in secondary infections with a different serotype, indicating
that pre-existing heterologous immunity may in certain instances
aggravate the infection outcome [122,126]. After a primary infec-
tion, the patients appear to be transiently protected from hetero-
typic infection, but this effect vanishes over time to render the
individuals more vulnerable to severe forms of the disease upon
subsequent heterotypic infection [127]. A recent study of a long-
term pediatric cohort in Nicaragua revealed that the risk of severe
dengue was correlated with pre-existing dengue antibody titers and
was significantly higher when the titers were low [128]. A similar
disease enhancement phenomenon of heterologous dengue infec-
tions had also been shown experimentally, four decades ago
already, with non-human primates that received antibodies against
dengue virus from human immune serum [129].
More recently, cross-enhancement was also shown between Zika
and dengue viruses, both in vitro [130,131] and in vivo using mouse
models [112,132]. In their analysis of Zika virus infections in mice,
Bardina et al [132] observed that antibody-dependent disease
enhancement was not only caused by human sera from dengue but
also from West Nile virus infections, albeit to lower extents and
frequencies. An extension of the phenomenon beyond dengue and
Zika viruses was also suggested by a recent study showing that
subjects with cross-reactive antibody titers from a prior inactivated
Japanese encephalitis vaccination had a prolonged yellow fever
vaccine viremia upon yellow fever vaccination [130]. In this case,
antibody-enhanced infection of the attenuated 17D yellow fever
vaccine strain had a beneficial effect by inducing higher titers of
neutralizing antibodies against yellow fever virus in these vacci-
nees.
To what extent cross-enhancement contributes to the pathogene-
sis of Zika or dengue infections in humans is still unresolved. So far,
studies in rhesus macaques did not find an influence of previous
infections with dengue or yellow fever viruses on Zika virus patho-
genesis [133,134], although in vitro ADE was clearly demonstrable
with the sera from these animals. Possible effects of pre-existing fla-
vivirus immunity on the teratogenic potential of Zika virus infec-
tions have not yet been analyzed in non-human primates (NHPs).
Nevertheless, a recent study in rhesus macaques provides the first
in vivo evidence that dengue infections can be significantly
enhanced by pre-existing immunity to Zika virus [135].
Neutralizing antibodies can override ADE Several studies have
shown that potently neutralizing antibodies can block the activity of
enhancing antibodies, both in vitro and in vivo [112,121,131]. Such
an ADE blocking activity is displayed by some but not all strongly
neutralizing antibodies, as revealed by an analysis of antibodies
engineered with a mutation at the site recognized by the Fcc recep-
tors (LALA mutants [136]) in a mouse model of antibody-enhanced
lethal dengue virus serotype 2 infections [121]. In this case, inhibi-
tion of disease enhancement was related to the capacity of the
blocking antibody to out-compete the enhancing antibodies for bind-
ing to the virion, and this concept formed the basis for the develop-
ment of an in vitro suppression-of-enhancement assay [121]. It is,
however, not necessary that the neutralizing antibody out-competes
ADE-prone antibodies bound to cryptic epitopes to override ADE. It
is sufficient to complete the antibody coating of the particle (Fig 5B)
by binding the remaining available sites on the virion that are left
unhindered by the already bound enhancing antibodies, without
displacing them.
After Fcc receptor-mediated virus uptake in the form of
immune complexes, only antibodies capable of preventing endoso-
mal fusion will be able to inhibit infection. This mechanism of
neutralization requires stability of the virus-antibody complex at
acid pH, a property usually reflected by bell-shaped curves of
in vitro ADE analyses, that is, enhancement at low antibody
concentrations but neutralization at high concentrations. Some
antibodies that are potently neutralizing in Fcc receptor-negative
cells, however, cause ADE also at high concentrations. Examples
are the EDE2 MAbs A11 and B7, which neutralize Zika virus infec-
tion of Vero cells with IC50s in the nanomolar range [69], but
which also enhance infection of Fcc receptor + U937 cells at
concentrations over 2 logs higher [131]. The Zika virus-specific
human Mab ZKA 230 [112] is another example of a potently
neutralizing antibody that enhances infection also at high concen-
trations. In these cases, it is likely that the antibody binding does
not withstand the acidic pH in the endosomes, and the neutraliza-
tion mechanism is restricted to blocking attachment.
EMBO reports Vol 19 | No 2 | 2018 ª 2017 Institut Pasteur
EMBO reports Flaviviruses and interactions with antibodies Félix A Rey et al
216
Considerations for in vitro neutralization as correlate for protection
The occurrence of breakthrough infections after vaccination with
the recently licensed dengue vaccine [12,13] in individuals who had
positive titers of neutralizing antibodies against the infecting sero-
type [137] raised concerns about the value of in vitro neutralization
as correlate for in vivo protection [106,138]. A lack of correlation
has also been suggested by previous studies of secondary dengue
infections in children despite the presence of neutralizing antibodies
against the infecting serotype [123].
Although correlation between neutralizing antibody titers against
dengue virus and protection from symptomatic infection was
observed by following a longitudinal cohort of patients [139], clini-
cally overt disease despite the presence of neutralizing antibodies
against the re-infecting serotype was also apparent in this study. For
the vaccines against yellow fever, Japanese encephalitis, and tick-
borne encephalitis, it is generally accepted that the responses
measured by in vitro neutralization correlate with protection [140],
but specific data on neutralizing antibody titers at the time of break-
through infections—similar to those generated in the course of the
Dengvaxia field trials [106]—are not available. It is therefore
currently not possible to establish an unambiguous comparison of
this parameter between the various vaccines.
Most virus neutralization measurements—especially with dengue
viruses—employ laboratory strains that have undergone multiple
passages and have adapted for better growth in tissue culture. The
higher degree of particle dynamics of the laboratory strains
compared to primary isolates discussed above [33,34,58,59] can
also affect the results of neutralization and/or ADE assays because
of differences in the exposure of certain epitopes, such as the FLEs
[82]. In a very interesting study, Chaichana et al [83] demonstrated
that human dengue post-infection sera strongly neutralized the
primary virus isolates obtained from the same patient, but failed to
neutralize laboratory-adapted strains. The opposite was seen in ADE
assays, that is, strong ADE with laboratory-adapted strains but no
ADE with the primary virus isolates. The antigenic heterogeneity of
dengue virus serotypes observed by Katzelnick et al [141] is also a
reflection of strong quantitative differences in the neutralization of
different virus strains by the same serum sample. Whether these
discrepancies are caused by differences in breathing or by antigenic
differences between strains remains to be further clarified.
Using in vitro neutralization as correlate for in vivo protection is
further challenged by variability in the extent of prM cleavage,
which is a virus strain-specific property but also a cell-dependent
variable that can affect antigenic reactivity (see above) and there-
fore affect the results of in vitro neutralization. The problem can be
partly overcome by the use of cell lines that overexpress furin and
thus lead to the production of homogeneous mature virus prepara-
tions [142]. Whether such a standardized setting, however, reflects
the situation in vivo remains to be elucidated.
Because of the discrepancies of in vitro neutralization and protec-
tion observed in the Dengvaxia study [106] and the potential impact
of ADE in the pathogenesis of dengue and possibly other flavivirus
infections, the use of Fcc receptor-bearing cell lines for in vitro
neutralization has been proposed as an alternative for yielding
better correlates for protection in humans [143]. These cells can be
tuned to express a set of Fcc receptors closely mimicking those on
natural target cells such as primary monocytes and are likely to
measure primarily the capacity of antibodies to inhibit viral
membrane fusion in the endosome. The induction of these antibod-
ies may be desirable for any flavivirus vaccine (see below “Implica-
tions for immunogen design”) because of the universality of the
inhibition of membrane fusion as a mechanism of virus neutraliza-
tion in all cell types. Antibodies that are unable to inhibit fusion but
neutralize by other mechanisms, however, may not be detected by
such assays, and a comparative analysis of dengue post-vaccination
sera in Fcc receptor-negative and Fcc receptor-positive cells would
be required to really inform about the quality of the correlation of
these two settings. Careful analyses will be necessary to evaluate
whether the proposed assay formats can be standardized to a simi-
lar degree as the conventional neutralization tests.
The many variables influencing the effects of antibody interac-
tions with heterogeneous and dynamic dengue virus particles circu-
lating in patients make the correlation of in vitro neutralization with
in vivo protection a topic of intensive discussion among stakehold-
ers in the area of dengue vaccines. Outstanding questions in our
understanding of protective or detrimental immune responses to
dengue virus infections and vaccinations were recently the focus of
a “Summit on Dengue Immune Correlates of Protection” and are
excellently summarized by Katzelnick et al [144]. It is apparent that
differences in the nature of vaccines as well as the status of fla-
vivirus immunity at the time of vaccination will affect the specifics
of immune responses and make the correlation between protection
and in vitro parameters even more difficult. Assay standardization is
one of the keys to further improvement in this area, but can only
complement future research into existing imponderables of immune
responses to dengue virus infections or vaccination and their impact
on protection from disease.
Use of antibodies for passive immunization
Potently neutralizing Mabs were shown to be protective in several
animal models of Zika and dengue virus infections when adminis-
tered before or even a short period after infection (reviewed in
[37,39,145]). These animal studies are encouraging for developing
therapeutic human antibodies to be used in pre- and post-exposure
treatments. A difficulty is that the time point of infection is usually
unknown, and the relatively short half-life of antibodies as well as
high costs are further limiting factors for large-scale and long-term
antibody-based immunization practices. Nevertheless, such strate-
gies may be of value in specific instances when protection is needed
for a certain period of time only, for instance to protect against Zika
virus infection during pregnancy. Recent data from a mouse model
have shown that an EDE antibody (containing the LALA mutation
to prevent FccR interactions and ADE effects [121,146,147]) is able
to protect adult mice from Zika and dengue virus-induced disease
and also to prevent fetal infection with Zika virus [148]. This dual
protection is consistent with the cross-neutralization patterns
observed with EDE antibodies (see Section “EDE Antibodies”
above) and would be an important benefit for application in preg-
nant women, considering that most of Zika virus infections have
occurred in countries endemic for dengue.
A possible concern could be the development of neutralization
escape mutants, which are readily selected when viruses replicate in
the presence of single Mabs. The problem may be solved by the use
of cocktails of potently neutralizing Mabs that are specific for dif-
ferent epitopes and thus prevent ready escape from neutralization.
In this context, an innovative concept of antibody engineering has
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been presented by Wang et al [149], who constructed a recombi-
nant tetravalent symmetric antibody out of two strongly Zika virus-
neutralizing human Mabs, one specific for domain III and one for
domain II. Tetravalency was achieved by fusing the Fab of the
domain III-Mab to the N-terminus of the domain II-Mab through a
flexible linker. The tetravalent antibody was further engineered with
a LALA mutation to prevent ADE. This chimeric antibody was
highly protective against Zika virus infection in a mouse model,
neutralized escape mutants generated by each of the parent antibod-
ies individually, and did not allow escape mutants to grow during
eight passages in vitro. In conclusion, rapid progress in the genera-
tion and engineering of human antibodies is being made which may
offer valuable opportunities for passive immunotherapies in specific
situations.
Implications for dengue immunogen design
Put together, the available data converge to indicate that, for efficient
flavivirus neutralization, the epitope’s accessibility is as crucial as the
binding affinity of the antibody. Only when these two conditions are
met, particle coating by the antibody can readily reach the stoichiom-
etry threshold required for neutralization. Moreover, when affinity is
high but accessibility is poor, the ADE potential is high. Antibodies
that are strongly neutralizing thus target readily accessible epitopes
on the E protein at the virion surface, whereas poorly neutralizing/
ADE-prone antibodies target cryptic epitopes. As the virion-exposed E
surface is mostly variable, and the buried E surfaces are mostly
conserved, it follows that the strongly neutralizing antibodies are
mostly serotype specific, while the broadly cross-reactive antibodies
are poorly neutralizing and ADE prone. In the case of dengue virus,
the exception to these general principles are the EDE antibodies,
which are cross-reactive as they bind to several flaviviruses—
although not as broad as the FLE antibodies, which bind to the E
protein of essentially all medically relevant flaviviruses—yet the EDE
Mabs potently neutralize the virus particles to which they bind.
Current vaccine approaches against dengue virus have not consid-
ered the implications of partial maturation and particle dynamics of
the immunogen. A number of vaccines use a mixture of four live-atte-
nuated chimeric viruses, containing the prM-E genome portion of the
four serotypes of dengue virus [150], but the properties of the particu-
lar dengue virus strain from which the prM/E segments were derived
have not been analyzed, neither with respect to their breathing behav-
ior nor to their maturation status. This is particularly important as the
furin cleavage site in dengue viruses appears to have been selected to
be suboptimal [15], resulting in the production of mostly partially
mature particles, which expose the FLEs and prM (Fig 3), and there-
fore induce ADE-prone antibodies. A proper selection of strains with
optimal furin cleavage sites in prM and lowest possible “breathing”
behavior of protein E would provide important advantages. Neverthe-
less, in a live vaccine the E protein must remain metastable to be able
to induce membrane fusion for entry—so that a certain level of breath-
ing must remain. In addition, complete prM processing does not
depend only on an optimal cleavage site but also on the levels of furin
present in the cells of the various tissues in which the vaccine repli-
cates, which are out of the experimenter’s control.
It is possible, in contrast, to control these properties experimen-
tally in the context of the development of a subunit vaccine. In such
an approach, (i) the E protein can be engineered to eliminate breath-
ing and (ii) prM can be eliminated altogether. A number of studies
have explored vaccines that rely on virus subunits, like DNA immu-
nisation with plasmids coding for domain III of the Envelope
protein of dengue virus [151], or the use of particles formed by the
hepatitis B core antigen exposing domain III of the the dengue virus
[152] and of the Zika virus E protein [153]. Also, an mRNA vaccine
platform encoding a mutated prM/E gene of Zika virus was
reported, in which the fusion loop was mutated to avoid eliciting
antibodies targeting the FLEs [154]. The drawback of this approach
is that, as the fusion loop is important for the E dimer interactions,
most mutations will interfere with dimer formation, exposing
other conserved regions of the E monomer normally buried in
the dimer (Fig 4). Furthermore, antibodies targeting quaternary
epitopes, which are among the most strongly neutralizing, will not
be elicited—the same is true for the particles exposing only domain
III mentioned above.
Recent studies have also shown that cysteine residues can be
engineered at strategic locations on E to make inter-subunit disulfide
bonds and stabilize the dimer [155,156]. These engineered disulfide
bridges prevent the dissociation of the dimer into monomers and
the exposure of the FLEs, which would occur at low concentrations.
The crystal structures of these covalently linked sE dimers were
indistinguishable from wild-type dimers [155]. Two different
cysteine mutants were generated: The first approach involved one
mutation at the center of the dimer (A259C in dengue virus serotype
2), such that the engineered C259 faces itself at the twofold molecu-
lar axes of the sE dimer to make a disulfide bond. The second
approach involved a double mutation—L107C and T313C in dengue
virus serotype 2—resulting in two cysteines facing each other across
the dimer interface, where the fusion loop (which contains residue
107) contacts domain III of the adjacent subunit. Importantly, in
ELISA experiments using immobilized sE, the EDE antibodies bound
efficiently to the cysteine mutants and not to wild-type E—which is
immobilized essentially as monomer, therefore not exposing dimer-
dependent epitopes. But the FLE antibodies bound efficiently to both
wild-type E and the A259C mutant, indicating that even with a cova-
lently stabilized dimer there is enough breathing of the E protein
about the central disulfide bond to allow binding of FLE Mabs. This
mutant also retained a certain degree of interaction with liposomes,
as assayed by co-flotation in density gradients at acid pH, consistent
with exposure of the fusion loop. The double cysteine mutant, in
contrast, did not react with most of the FLE antibodies and was
unable to co-float with liposomes, demonstrating that it is possible
to generate recombinant immunogens that stably display the EDE
but do not expose the fusion loop [155].
An issue remains about exposure of the dimer’s “underside”,
which is highly conserved (Fig 4A, right panel) and would be
exposed if isolated stabilized dimers were used as immunogens. The
ideal scaffold would be to present the E dimer as on the virion,
assembled into a herringbone pattern of 90 covalently linked
dimers, which would not expose the underside. How to obtain these
particles is not trivial, however, as the herringbone lattice is formed
only after the initial budding of immature particles with 60 spikes of
prM/E heterodimers (Fig 1). But it should be possible to find condi-
tions to drive a similar assembly, or to use other scaffolds to present
correctly stabilized dimers and masking their conserved side. An
alternative would be to re-surface the underside of the sE dimer,
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similar to the re-surfaced HIV gp120 that has been used to isolate
antibodies targeting the CD4 binding site [157].
The above approach should lead to the induction of strongly
neutralizing antibodies that target the variable, exposed side of the
E dimer. Because of the relative conservation of the EDE, which is
also exposed by the stabilized dimers, an adequate priming and
boosting strategy using two different E protein immunogens that
only have the EDE in common (such as using the E protein from
Zika virus and from any of the four dengue virus serotypes) should
focus the immune system into producing antibodies targeting the
EDE. In addition, the N-linked glycan on the 150 loop could be engi-
neered out to avoid inducing EDE2 antibodies, which require the
glycan to bind and were shown to induce ADE against Zika virus.
Such engineered immunogens should result in broad protection
while avoiding induction of unwanted antibodies with ADE poten-
tial. Because the presence of strongly neutralizing antibodies has
been shown to override ADE (see above) [89,112,121,131], this
vaccine approach should be valid not only for flavivirus naı¨ve indi-
viduals, but also in endemic countries where previous dengue infec-
tions may have induced ADE-prone antibodies in the population. In
other words, it should be possible to use the positive side of the
original antigenic sin phenomenon, by boosting cross-reactive anti-
bodies targeting the EDE while avoiding to boost those against the
FLEs. The identification of the EDE has therefore opened a new
window of opportunity for next-generation, EDE-focused subunit
vaccine design with a broad impact.
Conclusions and outlook
The advances made in the structural biology of flaviviruses have led
to unprecedented insight into the interactions of viruses with
antibodies, and into the effects these interactions can have on the
different steps of the cell entry process. Especially in the case of
dengue viruses, the much-debated Janus-faced nature of antibody
responses—beneficial and protective on the one hand but poten-
tially harmful on the other (causing ADE of infection in certain
constellations of sequential infections)—has hampered the develop-
ment of effective dengue vaccines for decades. In this context, it is
worth noting that the manufacturer of the sole dengue vaccine on
the market (Dengvaxia) recently released a statement (www.sanof
ipasteur.com/en/Documents/PDF/PR/20171130_Sanofi-Updates-Inf
o-on-Dengue-Vaccine_EN.pdf) and that a 6-year study revealed
more severe dengue disease in vaccinated individuals who were
naı¨ve to dengue virus at the time of vaccination, indicating that the
vaccine was protective only in individuals with prior dengue infec-
tions [158]. In the last years, the strong suspicion that cross-reactive
antibodies induced by previous dengue infections may have contrib-
uted to the observed pathogenesis of Zika virus infections—most of
which have occurred in dengue hyperendemic regions—has brought
the issue of antibody cross-reactivity without cross-neutralization to
the frontline. High-resolution analyses of the antigenic determinants
and detailed structural features of the epitopes, in combination with
functional studies of the corresponding antibodies, have dramati-
cally increased our mechanistic understanding of the virus neutral-
ization process and the antibody-mediated infection enhancement
phenomena. Efforts to put this information into practice to design
next-generation vaccines, focusing the antibody response on the
most protective antigenic sites, are underway, but remain challeng-
ing (see Box 1).
The recent progress in the area of flavivirus structural biology has
also made clear that there are still fundamental gaps in our under-
standing of the flavivirus entry process and the way it is inhibited or
enhanced by antibodies. Properties such as the heterogeneity of the
viral particles due to incomplete proteolytic maturation, and the
highly dynamic behavior of the virions, have been demonstrated with
viruses grown in vitro. This situation can affect the correlation
between antibody-mediated virus neutralization in vitro and protec-
tion in vivo. It is possible that structural heterogeneity and dynamic
behavior are key features required for flaviviruses to replicate effi-
ciently in phylogenetically distant hosts such as arthropods and verte-
brates. Understanding how these properties can affect antibody
responses and protection in vivo will certainly form important topics
of future research and inform the development of effective vaccines
Box 1: In need of answers
(i) How heterogeneous are naturally circulating flavivirus particles?
Studies so far were performed with viruses grown in cell culture
and revealed heterogeneities with respect to prM cleavage as well
as viral envelope dynamics, both of which can affect the induction
of and interaction with antibodies. Structural analyses of viruses
circulating in humans are challenging but will be critical for
understanding flavivirus immune responses.
(ii) What entry mechanisms are used in different tissues of infected
humans? What receptors are involved?
Current data on flavivirus receptors are diverse and inconclusive
as to their role in the infection of different tissues and the organ-
otropism of different flaviviruses. Similar to the interaction with
antibodies, structural heterogeneity and dynamics can provide a
number of interaction partners for cellular molecules that may
function as attachment and/or entry receptors in different tissues
and in different hosts.
(iii) How important is the ADE effect in Zika virus infections?
Epidemiological evidence indicates that the risk of severe forms of
dengue disease is substantially higher in sequential infections with
heterologous dengue virus serotypes than after primary infections
and this finding has been linked to ADE. In vitro and in vivo data
suggest that there may also be an association between pre-
existing dengue immunity and enhancement of Zika virus infec-
tions. Conclusive answers to this question will be important for
understanding the epidemiology of Zika disease and for informing
vaccine design. An important, related question is what would be
the impact of the immune status induced by a Zika vaccine during
subsequent dengue infections.
(iv) Can neutralization assays be improved to become a better corre-
late of protection?
Studies with dengue post-vaccination sera have revealed discrep-
ancies between in vitro neutralization of a given serotype and
protection from natural infection with the same serotype. Research
into better defining in vitro correlates of protection is of utmost
importance for the evaluation of immune responses to different
kinds of vaccines and their regulatory approval.
(v) Can a dengue or Zika vaccine be designed to avoid inducing ADE-
prone antibodies?
Studies with monoclonal antibodies have provided detailed struc-
tural insights into the characteristics of sites in the viral envelope
that can induce potently neutralizing and protective antibodies
and those that induce ADE-prone antibodies. Exploiting this infor-
mation is expected to inform the design of novel immunogens and
immunization schedules to maximize vaccine-induced protection.
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(Box 1). But the lessons derived from the ensemble of available stud-
ies already provide new leads toward the goal of next-generation
immunogens that selectively target the “bright” side of the immune
response, that is, protection from disease, in such a way that it domi-
nates over potentially harmful effects. In particular, the gained knowl-
edge that it is crucial to avoid exposure to the immune system of
conserved cryptic elements of the envelope protein, or exposure of
elements exposed only in immature flavivirus particles, paves the
way to novel approaches for vaccine design—in particular to protect
against dengue disease—with brighter prospects to provide better
protection to the general population.
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